These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 26186486

  • 1. Differential regulation of Tregs and Th17/Th1 cells by a sirolimus-based regimen might be dependent on STAT-signaling in renal transplant recipients.
    Li Y, Shi Y, Liao Y, Yan L, Zhang Q, Wang L.
    Int Immunopharmacol; 2015 Sep; 28(1):435-43. PubMed ID: 26186486
    [Abstract] [Full Text] [Related]

  • 2. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells.
    Gallon L, Traitanon O, Yu Y, Shi B, Leventhal JR, Miller J, Mas V, L X, Mathew JM.
    Transplantation; 2015 Sep; 99(9):1774-84. PubMed ID: 25905982
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ, Felipe CR, Tedesco-Silva H, Osmar Medina-Pestana J.
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients.
    Kim KW, Chung BH, Kim BM, Cho ML, Yang CW.
    Immunology; 2015 Jan; 144(1):68-78. PubMed ID: 24974886
    [Abstract] [Full Text] [Related]

  • 7. CNI induced Th17/Treg imbalance and susceptibility to renal dysfunction in renal transplantation.
    Li Y, Shi Y, Huang Z, Bai Y, Niu Q, Cai B, Wang L, Feng W.
    Int Immunopharmacol; 2011 Dec; 11(12):2033-8. PubMed ID: 21911083
    [Abstract] [Full Text] [Related]

  • 8. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor.
    Niemczyk M, Zegarska J, Pawłowska M, Wyzgał J, Ciszek M, Paczek L.
    Transpl Immunol; 2009 Jan; 20(3):139-42. PubMed ID: 18834941
    [Abstract] [Full Text] [Related]

  • 9. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Jan; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 10. The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo.
    Libetta C, Sepe V, Zucchi M, Portalupi V, Meloni F, Rampino T, Dal Canton A.
    Kidney Int; 2007 Jul; 72(1):114-20. PubMed ID: 17410097
    [Abstract] [Full Text] [Related]

  • 11. The imbalance between Tregs, Th17 cells and inflammatory cytokines among renal transplant recipients.
    Ma L, Zhang H, Hu K, Lv G, Fu Y, Ayana DA, Zhao P, Jiang Y.
    BMC Immunol; 2015 Sep 23; 16():56. PubMed ID: 26400627
    [Abstract] [Full Text] [Related]

  • 12. Sirolimus did not affect CD4(+)CD25(high) forkhead box p3(+)T cells of peripheral blood in renal transplant recipients.
    Chu ZQ, Ji Q.
    Transplant Proc; 2013 Sep 23; 45(1):153-6. PubMed ID: 23375290
    [Abstract] [Full Text] [Related]

  • 13. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ, Garbade J, Bittner HB, Fiedler M, Dhein S, Thiery J, Mohr FW, Gummert JF.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2011-7. PubMed ID: 17161355
    [Abstract] [Full Text] [Related]

  • 14. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 15. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study.
    Pankewycz O, Leca N, Kohli R, Weber-Shrikant E, Said M, Alnimri M, Feng L, Patel S, Laftavi MR.
    Transplant Proc; 2011 Mar 15; 43(2):519-23. PubMed ID: 21440749
    [Abstract] [Full Text] [Related]

  • 16. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV, Felipe CR, Campos ÉF, de Lima MG, Soares MF, de Franco MF, Aguiar WF, Tedesco-Silva H, Medina-Pestana JO.
    Transplantation; 2015 Nov 15; 99(11):2372-81. PubMed ID: 25929604
    [Abstract] [Full Text] [Related]

  • 17. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 15; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 18. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity.
    Ghazal K, Stenard F, Dahlqvist G, Barjon C, Aoudjehane L, Scatton O, Conti F.
    Clin Res Hepatol Gastroenterol; 2018 Jun 15; 42(3):237-244. PubMed ID: 29175009
    [Abstract] [Full Text] [Related]

  • 19. Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation.
    Egbuna OI, Davis RB, Chudinski R, Pavlakis M, Rogers C, Molakatalla P, Johnson SR, Karp S, Monaco AP, Tang H, Hanto DW, Mandelbrot DA.
    Transplantation; 2009 Sep 15; 88(5):684-92. PubMed ID: 19741466
    [Abstract] [Full Text] [Related]

  • 20. Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients.
    Levitsky J, Mathew JM, Abecassis M, Tambur A, Leventhal J, Chandrasekaran D, Herrera N, Al-Saden P, Gallon L, Abdul-Nabi A, Yang GY, Kurian SM, Salomon DR, Miller J.
    Hepatology; 2013 Jan 15; 57(1):239-48. PubMed ID: 22234876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.